Eri R, Jonsson J R, Pandeya N, Purdie D M, Clouston A D, Martin N, Duffy D, Powell E E, Fawcett J, Florin T H J, Radford-Smith G L
Brisbane IBD Research Group, Clinical Research Centre, Royal Brisbane Hospital Research Foundation, Brisbane, Australia.
Genes Immun. 2004 Sep;5(6):444-50. doi: 10.1038/sj.gene.6364113.
CCR5 plays a key role in the distribution of CD45RO+ T cells and contributes to generation of a T helper 1 immune response. CCR5-Delta32 is a 32-bp deletion associated with significant reduction in cell surface expression of the receptor. We investigated the role of CCR5-Delta32 on susceptibility to ulcerative colitis (UC), Crohn's disease (CD) and primary sclerosing cholangitis (PSC). Genotype and allelic association analyses were performed in 162 patients with UC, 131 with CD, 71 with PSC and 419 matched controls. There was a significant difference in CCR5 genotype (OR 2.27, P=0.003) between patients with sclerosing cholangitis and controls. Similarly, CCR5-Delta32 allele frequency was significantly higher in sclerosing cholangitis (17.6%) compared to controls (9.9%, OR 2.47, P=0.007) and inflammatory bowel disease patients without sclerosing cholangitis (11.3%, OR 1.9, P=0.027). There were no significant differences in CCR5 genotype or allele frequency between those with either UC or CD and controls. Genotypes with the CCR5-Delta32 variant were increased in patients with severe liver disease defined by portal hypertension and/or transplantation (45%) compared to those with mild liver disease (21%, OR 3.17, P=0.03). The CCR5-Delta32 mutation may influence disease susceptibility and severity in patients with PSC.
CCR5在CD45RO + T细胞的分布中起关键作用,并有助于产生辅助性T细胞1免疫反应。CCR5-Delta32是一种32个碱基对的缺失,与该受体细胞表面表达的显著降低有关。我们研究了CCR5-Delta32对溃疡性结肠炎(UC)、克罗恩病(CD)和原发性硬化性胆管炎(PSC)易感性的作用。对162例UC患者、131例CD患者、71例PSC患者和419例匹配对照进行了基因型和等位基因关联分析。硬化性胆管炎患者与对照之间的CCR5基因型存在显著差异(比值比2.27,P = 0.003)。同样,与对照(9.9%,比值比2.47,P = 0.007)和无硬化性胆管炎的炎症性肠病患者(11.3%,比值比1.9,P = 0.027)相比,硬化性胆管炎患者的CCR5-Delta32等位基因频率显著更高。UC或CD患者与对照之间的CCR5基因型或等位基因频率没有显著差异。与轻度肝病患者(21%,比值比3.17,P = 0.03)相比,由门静脉高压和/或移植定义的严重肝病患者中携带CCR5-Delta32变异的基因型增加(45%)。CCR5-Delta32突变可能影响PSC患者的疾病易感性和严重程度。